Revenue
2022
2023
2024
2025
Phathom Pharmaceuticals, Inc. (PHAT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682,000 | $0 | — | — | — | — |
| Gross profit | $152.5M | $47.3M | $515,000 | $0 | — | — | — | — |
| Research & development | $32.8M | $34.1M | $49.9M | $71.4M | $72.3M | $98.1M | $20.4M | $20,000 |
| Operating expenses | $312.5M | $324.7M | $167.8M | $172.4M | $135.1M | $125.7M | $106.2M | $1.2M |
| Operating income | −$160.0M | −$277.5M | −$167.3M | −$172.4M | −$135.1M | −$125.7M | −$106.2M | −$1.2M |
| EBITDAderived | −$159.4M | −$276.7M | −$166.7M | −$171.8M | −$134.6M | −$125.3M | −$106.2M | — |
| Net income | −$221.2M | −$334.3M | −$201.6M | −$197.7M | −$143.9M | −$129.1M | −$255.1M | −$1.3M |
| Basic EPSper diluted share | -$3.03 | -$5.29 | -$3.93 | -$5.05 | -$3.89 | -$3.88 | -$22.45 | -$0.21 |
| Diluted EPSper diluted share | -$3.03 | -$5.29 | -$3.93 | -$5.05 | -$3.89 | -$3.88 | -$22.45 | -$0.21 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 3, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 524 | $13.51 | $7.1K | 47.4K |
| Sep 5, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 461 | $12.09 | $5.6K | 47.9K |
| Jul 16, 2025Form 4 | Breedlove Robert CharlesPrincipal Accounting Officer | SellCommon Stock | 1.7K | $8.36 | $14.1K | 48.4K |
| May 21, 2025Form 4 | Topper James NDirector | BuyCommon Stock · indirect | 3.8K | $3.86 | $14.6K | 59.4K |
| May 14, 2025Form 4 | Topper James NDirector | BuyCommon Stock · indirect | 6.3K | $3.32 | $20.9K | 55.6K |